アブストラクト
Japanese
| Title | 重症筋無力症の治療アルゴリズム |
|---|---|
| Subtitle | 第37回日本神経治療学会総会特集1 シンポジウム7 : 免疫性神経疾患診療の最前線 - 4 |
| Authors | 村井弘之** |
| Authors (kana) | |
| Organization | **国際医療福祉大学医学部脳神経内科学 |
| Journal | 神経治療学 |
| Volume | 37 |
| Number | 3 |
| Page | 421-424 |
| Year/Month | 2020 / |
| Article | 報告 |
| Publisher | 日本神経治療学会 |
| Abstract | 「はじめに」 重症筋無力症(myasthenia gravis : MG)の治療は近年大きく変貌している. 以前は全身型MGでは胸腺腫の有無にかかわらず胸腺摘除術を行い, 大量の経口ステロイドを使用するという治療法がゴールドスタンダードであった. たしかにこのおかげでMGの死亡率が大きく低下し, 治療成績が大きく伸びたのは事実である. しかし, 近年になり, 大量・長期のステロイド投与の弊害が顕在化してきた. 経口ステロイド量は生活の質(quality of life : QOL)と逆相関する. それと同時にMGの世界にもさまざまな治療手段が登場してきた. Tacrolimusやciclosporinなどの免疫抑制薬, 免疫グロブリン大量静注, ステロイドパルス療法, そして補体を阻害する分子標的薬eculizumabなどである. これらの新しい治療法をうまく組み合わせることにより, ステロイドを増量することなく全身型MGを治療することが可能になり, ひいては患者のQOLの向上につながっていくことが明らかとなってきている. |
| Practice | 臨床医学：内科系 |
| Keywords | myasthenia gravis, treatment, algorithm |
English
| Title | Treatment algorithm for myasthenia gravis |
|---|---|
| Subtitle | |
| Authors | Hiroyuki MURAI |
| Authors (kana) | |
| Organization | Department of Neurology, School of Medicine, International University of Health and Welfare |
| Journal | Neurological Therapeutics |
| Volume | 37 |
| Number | 3 |
| Page | 421-424 |
| Year/Month | 2020 / |
| Article | Report |
| Publisher | Japanese Society of Neurological Therapeutics |
| Abstract | Myasthenia gravis (MG) has been classified into six subgroups : ocular MG (OMG), early-onset MG (EOMG), late-onset MG (LOMG), thymoma-associated MG (TAMG), muscle-specific receptor tyrosine kinase antibody-positive MG (MuSK-MG), and seronegative MG (SNMG). The treatment strategies differ among these subgroups. Based on the Japanese Clinical Guidelines for MG published in 2014, treatment strategies for each subgroup are described and illustrated in the figure. This paper should be a help for physicians taking care of MG patients. |
| Practice | Clinical internal medicine |
| Keywords | myasthenia gravis, treatment, algorithm |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Murai H : Japanese clinical guidelines for myasthenia gravis : Putting into practice. Clin Exp Neuroimmunol 6 : 21-31, 2015
- 2) Murai H, Utsugisawa K, Nagane Y et al : Rationale for the clinical guidelines for myasthenia gravis in Japan. Ann NY Acad Sci 1413 : 35-40, 2018
- 3) Jaretzki A 3rd, Barohn RJ, Ernstoff RM et al : Myasthenia gravis : recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America(MGFA). Neurolo-gy 55 : 16-23, 2000
- 4) Murai H, Masuda M, Utsugisawa K et al : Clinical features and treatment status of adult myasthenia gravis in Japan. Clin Exp Neuroimmunol 5 : 84-91, 2014
- 5) Gilhus NE, Skeie GO, Romi F et al : Myasthenia gravis-au-toantibody characteristics and their implications for therapy. Nat Rev Neurol 12 : 259-268, 2016
残りの12件を表示する
- 6) Akaishi T, Yamaguchi T, Suzuki Y et al : Insights into the classification of myasthenia gravis. PLoS One 9 : e106757, 2014
- 7) Nagane Y, Utsugisawa K, Suzuki S et al : Topical naphazo-line in the treatment of myasthenic blepharoptosis. Muscle Nerve 44 : 41-44, 2011
- 8) Yagi Y, Sanjo N, Yokota T et al : Tacrolimus monotherapy : a promising option for ocular myasthenia gravis. Eur Neurol 69 : 344-345, 2013
- 9) Wolfe GI, Kaminski HJ, Aban IB et al : Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med 375 : 511-522, 2016
- 10) Wolfe GI, Kaminski HJ, Aban IB et al : Long-term effect of thymectomy plus prednisone versus prednisone alone in pa-tients with non-thymomatous myasthenia gravis : 2-year ex-tension of the MGTX randomised trial. Lancet Neurol 18 : 259-268, 2019
- 11) Utsugisawa K, Nagane Y, Akaishi T et al : Early fast-acting treatment strategy against generalized myasthenia gravis. Muscle Nerve 55 : 794-801, 2017
- 12) Howard JF Jr, Utsugisawa K, Benatar M et al : Safety and efficacy of eculizumab in anti-acetylcholine receptor anti-body-positive refractory generalised myasthenia gravis(RE-GAIN): a phase 3, randomised, double-blind, placebo-con-trolled, multicentre study. Lancet Neurol, 2017
- 13) Muppidi S, Utsugisawa K, Benatar M et al : Long-term safe-ty and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60 : 14-24, 2019
- 14) Murai H, Uzawa A, Suzuki Y et al : Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis : A subgroup analysis of the REGAIN open-label extension study. J Neurol Sci 407 : 116419, 2019
- 15) Hehir MK, Hobson-Webb LD, Benatar M et al : Rituximab as treatment for anti-MuSK myasthenia gravis : Multicenter blinded prospective review. Neurology 89 : 1069-1077, 2017
- 16) Beecher G, Anderson D, Siddiqi ZA : Rituximab in refractory myasthenia gravis : Extended prospective study results. Mus-cle Nerve 58 : 452-455, 2018
- 17) Anderson D, Phan C, Johnston WS et al : Rituximab in re-fractory myasthenia gravis : a prospective, open-label study with long-term follow-up. Ann Clin Transl Neurol 3 : 552-555, 2016
